Medvi

At a glance

 

Cash-pay telehealth weight-loss platform offering provider-prescribed GLP-1 medications with home delivery; positioned as affordable, "no insurance required," doctor-supervised, with fast (24–48 hr) approval and all-inclusive monthly pricing. Reported founding 2023; San Diego, CA base with a BBB profile in Newark, DE. Site: medvi.com (funnels on medvi.org / getmedvi.com). Leadership not clearly disclosed — do not name executives; "MEDvidi" (mental health) is a separate company, do not conflate.

 

What they offer

 

Monthly membership bundling online intake, async + telehealth consult, prescribed GLP-1 medication, unlimited provider messaging, and home delivery. Marketing references dietitian/care-coaching and clinician review via partner networks (e.g., OpenLoop; pharmacy partner Belmar cited). Verify partner names at publish.

 

The offer / hook

 

Lead hook: compounded semaglutide injections "starting at $179" first month ( ~$299/mo thereafter), promoted as all-inclusive (medication + provider support). Verify live promo on the assigned landing page.

 

Key features & plans (verify each)

 

• Compounded semaglutide injection: ~$179 first month ~$299/mo.

 

• Compounded semaglutide tablets: ~$249 ~$369/mo.

 

• Compounded tirzepatide (injection/tablet): ~$279 ~$399/mo.

 

• Branded: Ozempic ~$1,999/mo cited; Wegovy/Zepbound priced at checkout ("$99 membership + medication").

 

• Bundled: medication, telehealth visits, unlimited messaging, shipping; some plans HSA/FSA-eligible.

 

How it works & eligibility

 

(1) Online medical evaluation (2) clinician reviews eligibility (BMI-based; 30, or 27 with condition — thresholds not clearly published) (3) telehealth consult/approval (4) ships to door. No insurance (cash-pay).

 

Pros

 

• All-inclusive monthly pricing (medication + provider support).

 

• Fast online intake/approval; home delivery.

 

• Lower entry price than branded GLP-1s; injection & oral options.

 

• Large volume of positive Trustpilot reviews.

 

Cons / watch-outs

 

• Cash-pay cost adds up; branded options expensive.

 

• Regulatory uncertainty (prominent): FDA declared semaglutide/tirzepatide shortages resolved (Feb 2025 / Oct 2024); 503A discretion for compounded semaglutide ended ~April 2025; 2026 FDA proposal to exclude these from the 503B bulks list. Compounded products are not FDA-approved.

 

• Subscription/auto-renewal; billing/refund/CS complaints (Reddit, ConsumerAffairs).

 

• Thinner public track record than Ro/Hims/Found; GLP-1 side effects.

 

Trust & ratings

 

• Trustpilot (medvi.org): "Excellent," ~4.4/5 across a large volume (one source cited 9,400+; verify). BBB (Newark, DE): not accredited. Strong Trustpilot vs refund/billing complaints elsewhere. No notable app-store presence confirmed.

 

Suggested editorial angle & headlines

 

Angle: "Affordable, convenient on-ramp to doctor-supervised GLP-1 treatment — for the right candidate, eyes open on cash cost and shifting compounding rules."

 

• MEDVi Review: GLP-1 Weight Loss From $179/Month, No Insurance Needed

 

• Is MEDVi Worth It? A Look at Its Telehealth GLP-1 Plans, Pricing, and Fine Print

 

• MEDVi vs. the Big GLP-1 Telehealth Brands: What You Get for the Price

 

CTA & disclosure notes (health compliance)

 

• No medical claims/guarantees; don't restate "6x" or patient-count claims as fact.

 

• Required: "Prescription products require an online consultation with a licensed healthcare provider who will determine if a prescription is appropriate."

 

• State clearly compounded GLP-1s are not FDA-approved; eligibility/availability subject to medical review and current regulations.

 

• CTA via assigned tracking link; affiliate disclosure + editorial-independence note; results vary, side effects possible.

 

Fact-check flags: confirm live starting price/promo; do not name founders or confuse with "MEDvidi"; compounded-GLP-1 rules changing 2025–2026 (never call compounded FDA-approved); treat "500,000+ patients" and "6x more weight loss" as vendor claims.

 

Sources: glp1.medvi.org · ConsumerAffairs · Bariatric Journal · GLP-1 Journal · Trustpilot · BBB (Newark, DE) · FDA (compounder policy; 503B bulks proposal).